Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Next Previous
Search
Trial Profile

A Phase I/II, Open-Label, Dose-Escalation Study Evaluating the Safety, Tolerability Pharmacokinetics and Pharmacodynamics of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 23 Jan 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Momelotinib (Primary)
  • Indications Myelofibrosis
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Gilead Sciences; Sierra Oncology

    • Most Recent Events

    • 12 Dec 2023 Results(n=79) presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 06 Dec 2016 Results of 6 years follow up data (n=100) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 08 Dec 2015 Results of retrospective analysis (n=100) presented at the 57th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top